Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369437 | 0.86 | LMNA (0.38) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL8772810 | 0.84 | TSHR (0.50) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL11801018 | 0.82 | LMNA (0.48) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL28382980 | 0.81 | — | — | |
| SCHEMBL28382979 | 0.81 | — | — | |
| SCHEMBL11096793 | 0.81 | TSHR (0.50) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL23548930 | 0.77 | APLNR (0.37) | — | |
| SCHEMBL26117541 | 0.77 | APLNR (0.37) | — | |
| SCHEMBL26113103 | 0.77 | APLNR (0.37) | — | |
| SCHEMBL26110454 | 0.77 | APLNR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4209130-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE ANIMAL FEED AND METHODS OF PRODUCING THEREOF | DSM Nutritional Products, LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4205553-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE ANIMAL FEED AND METHODS OF PRODUCING THEREOF | DSM Nutritional Products, LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-108026049-B | Compositions and methods for treating and preventing neurodegenerative disorders | 阿尔泽恩股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | ALZHEON, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3459975-A1 | POLYMERIC ACID CATALYSTS AND USES THEREOF | Cadena Bio, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3334710-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | Alzheon, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-108026049-A | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | 阿尔泽恩股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| EP-2681247-B1 | Polymers containing an acid group and their use as a catalyst | CADENA BIO INC (US) | 2018-04-04 | — | — | EP | disclosed |
| WO-2017027582-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016122887-A9 | OLIGOSACCHARIDE COMPOSITIONS FOR USE ANIMAL FEED AND METHODS OF PRODUCING THEREOF | MIDORI USA, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133465-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | LMNA 160/4885CYP3A4 4603/4885GABRA1 2674/4885 |
| US-11053192-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | LMNA 160/4885CYP3A4 4603/4885GABRA1 2674/4885 |
| US-12187668-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | LMNA 160/4885CYP3A4 4603/4885GABRA1 2674/4885 |
| US-10590070-B2 | Compositions and methods for treating and preventing neurodegenerative disorders | PSEN2, CLN6, PSEN1 | LMNA 160/4885CYP3A4 4603/4885GABRA1 2674/4885 |
| US-20200347012-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | PSEN2, CLN6, PSEN1 | LMNA 160/4885CYP3A4 4603/4885GABRA1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.